Evidence map›Paper›PMID 24727262›Full record

Trial reportAmerican journal of ophthalmology2014

Visual field improvement in the collaborative initial glaucoma treatment study.

David C Musch, Brenda W Gillespie, Paul F Palmberg, George Spaeth, Leslie M Niziol, Paul R Lichter

Open access · greenAbstract readComparative StudyMulticenter StudyRandomized Controlled Trial
In one paragraph

Trial report in American journal of ophthalmology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed, 1 pooled it
4.0field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 1 synthesis or guideline pooled it, 65 citations in OpenAlex.

  1. The effect of flavonoids on visual function in patients with glaucoma or ocular hypertension: a systematic review and meta-analysis.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2015
    Pooled it
  2. Phase 2b, Randomized, 3-Month, Dose-Finding Study of Sepetaprost in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension: The ANGEL Study.Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics · 2022
    Trial
  3. Trial
  4. Management and outcomes of primary open-angle glaucoma.Journal of family medicine and primary care · 2026
    Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Adaptive responses to neurodegenerative stress in glaucoma.Progress in retinal and eye research · 2021
    Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Observational
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

David C MuschDepartment of Ophthalmology and Visual Sciences, Medical School, University of Michigan, Ann Arbor, Michigan; Department of Epidemiology, School of Public Health, University of Michigan, Ann Arbor, Michigan. Electronic address: dmusch@med.umich.edu.
Brenda W GillespieDepartment of Biostatistics, School of Public Health, University of Michigan, Ann Arbor, Michigan.
Paul F PalmbergBascom Palmer Eye Institute, University of Miami, Miami, Florida.
George SpaethWills Eye Hospital, Philadelphia, Pennsylvania.
Leslie M NiziolDepartment of Ophthalmology and Visual Sciences, Medical School, University of Michigan, Ann Arbor, Michigan.
Paul R LichterDepartment of Ophthalmology and Visual Sciences, Medical School, University of Michigan, Ann Arbor, Michigan.
University of Michigan–Ann Arbor · USUniversity of Miami · USWills Eye Hospital · US

Funding

Insights on Glaucoma from Analysis of the CIGTS DataR21EY020912 · NEI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI MUSCH, DAVID C · 2011 to 2012
$426k
COLLABORATIVE INITIAL GLAUCOMA TREATMENT STUDYU10EY009148 · NEI · JOHNS HOPKINS UNIVERSITY · PI JAMPEL, HENRY D · 1993 to 2002
$275k
Statins To Prevent Progression of Glaucoma: The STOP Glaucoma TrialR34EY022399 · NEI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI MUSCH, DAVID C, STEIN, JOSHUA D · 2013 to 2013
$233k
NEI NIH HHS EY022399NEI NIH HHS EY09148NEI NIH HHS R21 EY020912NEI NIH HHS R34 EY022399
6 · The paper itself

Abstract

purposeTo evaluate critically visual field (VF) improvement in participants in the Collaborative Initial Glaucoma Treatment Study (CIGTS).

designProspective, comparative case series from a randomized clinical trial comparing trabeculectomy and topical medications in treating open-angle glaucoma (OAG).

methodsA total of 607 subjects with newly diagnosed OAG were identified for study. Baseline and follow-up VF tests were obtained and mean deviation (MD) change from baseline over follow-up was analyzed. Clinically substantial change (loss or improvement) was defined as change from baseline of ≥ 3 decibels in MD. Baseline factors were inspected to determine their association with VF improvement in repeated measures regression models.

resultsThe percentage of participants showing substantial VF improvement over time was similar to that showing VF loss through 5 years after initial treatment, after which VF loss became more frequent. Measures of better intraocular pressure (IOP) control during treatment were significantly predictive of VF improvement, including a lower mean IOP, a lower minimum IOP, and lower sustained levels of IOP over follow-up. Other predictive factors included female sex (odds ratio [OR] = 1.73), visits 1 year prior to cataract extraction (OR = 0.11), and an interaction between treatment and baseline MD wherein surgically treated subjects with worse baseline VF loss were more likely to show VF improvement.

conclusionsIn the CIGTS, substantial VF loss and improvement were comparable through 5 years of follow-up, after which VF loss became more frequent. Predictive factors for VF improvement included several indicators of better IOP control, which supports the postulate that VF improvement was real.

Indexed as

TrabeculectomyAdultAgedAntihypertensive AgentsFemaleFollow-Up StudiesGlaucoma, Open-AngleHumansIntraocular PressureMaleMiddle AgedProspective StudiesVision DisordersVisual AcuityVisual FieldsVisual Field TestsAntihypertensive Agents

Identifiers

PMID24727262
PMCPMC4190842
OpenAlexW2010254915

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.